ATM and diffuse large B-cell lymphoma: ATM-3507 treatment significantly reduced the ability of Toledo and NU-DUL-1 DLBCL cells to migrate toward CXCL12, a chemokine that directs the in vivo trafficking of both normal and malignant B cells (14, 77).